To conclude, TERT promoter mutations are predominantly found in the subgroups of malignant endocrine tumors, such as malignant PGL and adrenocortical cancer, and the observation of C228T mutations in 12% of ACCs adds a new cornerstone to the mutational panorama of these tumors. This evidence concerns the gene TERT and malignant endocrine neoplasm.